Biotech stocks are a monster roller-coaster. News of a potential blockbuster drug or pending merger—or, conversely, bad results in a clinical trial—can make prices soar or plunge 15% or more in a day. For all their volatility, though, biotechs have racked up big gains this year. Can they continue to buck the tech decline?
展开▼
